Eledon Pharmaceuticals, Inc. (ELDN) - Dilution Analysis

10-Q filing | 77.2M shares outstanding

S-3 filing: The company is offering up to $500,000,000 in aggregate principal amount of common stock, preferred stock, debt securities, warrants and/or units.

10-K filing | 81.8M shares outstanding

10-Q filing | 59.9M shares outstanding

10-Q filing | 59.9M shares outstanding

10-Q filing | 59.9M shares outstanding

10-K filing | 59.9M shares outstanding

10-Q filing | 55.5M shares outstanding

8-K filing: Eledon Pharmaceuticals, Inc. entered into an underwriting agreement for the offering, issuance and sale of 18,356,173 shares of common stock at $3.65 per share and pre-funded warrants to purchase 4,931,507 shares at an exercise price of $0.001 per share, with the Offering expected to close on or about October 30, 2024, resulting in estimated net proceeds of approximately $79.5 million.

8-K filing: Eledon Pharmaceuticals, Inc. completed the sale of 1,527,400 shares on September 30, 2024 and 200,000 shares on October 1, 2024 of its common stock, resulting in gross proceeds of approximately $4.0 million. ($4.0M proceeds)

S-3 filing: The company is offering up to $250,000,000 in aggregate principal amount of common stock, preferred stock, debt securities, warrants and/or units from time to time, and is also offering common stock in an at-the-market offering for pre-commercial activities for products, working capital and general corporate purposes.

10-Q filing | 42.3M shares outstanding

8-K filing: Eledon Pharmaceuticals, Inc. completed the sale of 909,088 shares of its common stock at $0.001 par value, resulting in gross proceeds of approximately $2.1 million. ($2.1M proceeds)

S-3 filing: This S-3 filing relates to the resale of up to 21,100,000 shares of common stock by selling stockholders, consisting of shares held by the selling stockholders and shares issuable upon the exercise of outstanding pre-funded warrants.

10-Q filing | 38.5M shares outstanding

8-K filing: Eledon Pharmaceuticals, Inc. entered into a Securities Purchase Agreement to issue and sell 13,110,484 shares of common stock at $2.37 per share and pre-funded warrants to purchase 7,989,516 shares of common stock at $2.369 per underlying share, resulting in gross proceeds of approximately $50 million. ($50.01M proceeds)

10-K filing | 24.6M shares outstanding

10-Q filing | 24.2M shares outstanding

10-Q filing | 24.0M shares outstanding

S-3 filing: This prospectus relates to the resale from time to time of up to 75,757,590 shares of our common stock by the selling stockholders.

10-Q filing | 22.5M shares outstanding

8-K filing: Eledon Pharmaceuticals, Inc. entered into a Securities Purchase Agreement for a private placement involving the issuance and sale of common stock and warrants to institutional and accredited investors in three closings, expected to result in gross proceeds of approximately $35 million in the initial closing, an additional $105 million in the second and third closings, and an additional $45 million assuming the exercise of all Common Warrants. ($140.0M proceeds)

10-K filing | 14.3M shares outstanding

10-Q filing | 14.3M shares outstanding

10-Q filing | 14.3M shares outstanding

10-Q filing | 13.8M shares outstanding

10-K filing | 14.3M shares outstanding

8-K filing: Eledon Pharmaceuticals, Inc. exchanged 550,000 shares of common stock for 9,899.99 shares of Series X1 Preferred Stock with Biotechnology Value Fund, L.P., Biotechnology Value Fund II, L.P., Biotechnology Value Trading Fund OS, L.P. , MSI BVF SPV, L.L.C.

10-Q filing | 14.3M shares outstanding

10-Q filing | 14.3M shares outstanding

10-Q filing | 14.3M shares outstanding

10-K filing | 14.3M shares outstanding

S-3 filing: The company is filing an S-3 to offer up to $250,000,000 in common stock, preferred stock, and/or debt securities, with a $75,000,000 portion of common stock to be offered through an at-the-market offering via Jefferies LLC, and plans to use the net proceeds for research and development relating to AT-1501, as well as for working capital and general corporate purposes.

S-3 filing: The filing is an S-3 form for the proposed resale of 12,364,568 shares of common stock by selling stockholders. The shares are issuable upon conversion of Series X1 Preferred Stock that was issued in a private placement transaction dated September 14, 2020 and upon conversion of Series X1 Preferred Stock underlying warrants that the Company assumed in connection with the acquisition of Anelixis Therapeutics, Inc. on September 14, 2020.

10-Q filing | 1.4M shares outstanding

10-Q filing | 19.4M shares outstanding

10-Q filing | 16.1M shares outstanding

S-1 filing: The selling stockholders are offering on a resale basis an aggregate of 7,243,135 shares of common stock issuable upon the exercise of outstanding warrants.

10-K filing | 16.1M shares outstanding